| Sep 16 |
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
|
| Sep 10 |
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
|
| Aug 23 |
Entero Therapeutics receives Nasdaq notification regarding delayed form 10-Q
|
| Aug 23 |
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
|
| Jul 31 |
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
|
| Jul 26 |
Entero Therapeutics files secondary offering of 3.5M shares
|
| Jul 11 |
Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds
|
| Jul 9 |
Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium
|
| Jun 27 |
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease
|
| May 22 |
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
|
